IL274098B2 - Glp-2 analogs and peptibodies for administration before during, or after surgery - Google Patents
Glp-2 analogs and peptibodies for administration before during, or after surgeryInfo
- Publication number
- IL274098B2 IL274098B2 IL274098A IL27409820A IL274098B2 IL 274098 B2 IL274098 B2 IL 274098B2 IL 274098 A IL274098 A IL 274098A IL 27409820 A IL27409820 A IL 27409820A IL 274098 B2 IL274098 B2 IL 274098B2
- Authority
- IL
- Israel
- Prior art keywords
- glp
- receptor agonist
- use according
- patient
- surgery
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762582055P | 2017-11-06 | 2017-11-06 | |
| PCT/US2018/059175 WO2019090209A1 (en) | 2017-11-06 | 2018-11-05 | Glp-2 analogs and peptibodies for administration before during, or after surgery |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL274098A IL274098A (en) | 2020-06-30 |
| IL274098B1 IL274098B1 (en) | 2024-08-01 |
| IL274098B2 true IL274098B2 (en) | 2024-12-01 |
Family
ID=66332372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL274098A IL274098B2 (en) | 2017-11-06 | 2018-11-05 | Glp-2 analogs and peptibodies for administration before during, or after surgery |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11660328B2 (https=) |
| EP (1) | EP3706774A4 (https=) |
| JP (2) | JP7296958B2 (https=) |
| KR (1) | KR102825098B1 (https=) |
| CN (1) | CN111629745A (https=) |
| AR (1) | AR113835A1 (https=) |
| AU (1) | AU2018360744A1 (https=) |
| BR (1) | BR112020008936A2 (https=) |
| CA (1) | CA3079523A1 (https=) |
| IL (1) | IL274098B2 (https=) |
| MX (1) | MX2020004620A (https=) |
| TW (1) | TWI911137B (https=) |
| WO (1) | WO2019090209A1 (https=) |
| ZA (1) | ZA202002080B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020003736A2 (pt) * | 2017-08-22 | 2020-09-08 | Shire-Nps Pharmaceuticals, Inc. | polipeptídeos de fusão de glp-2 e usos para tratar e prevenir condições gastrointestinais |
| JP2022512688A (ja) * | 2018-10-24 | 2022-02-07 | シャイア－エヌピーエス ファーマシューティカルズ インコーポレイテッド | Ｇｌｐ－２融合ポリペプチドならびに消化管の状態の処置および予防のための使用 |
| SG11202111311WA (en) | 2019-06-14 | 2021-12-30 | Zealand Pharma As | Pharmaceutical parenteral composition of dual glp1/2 agonist |
| KR20220150270A (ko) | 2019-10-07 | 2022-11-10 | 칼리오페, 인크. | Gpr119 효능제 |
| TW202140440A (zh) | 2020-02-28 | 2021-11-01 | 美商克力歐普股份有限公司 | Gpr40激動劑 |
| US20230129788A1 (en) * | 2020-03-30 | 2023-04-27 | Zealand Pharma A/S | Glp-1/glp-2 dual agonists |
| WO2021236617A1 (en) | 2020-05-19 | 2021-11-25 | Kallyope, Inc. | Ampk activators |
| CN116390925A (zh) | 2020-06-26 | 2023-07-04 | 卡尔优普公司 | Ampk活化剂 |
| WO2021263040A1 (en) * | 2020-06-26 | 2021-12-30 | Shire-Nps Pharmaceuticals, Inc. | Stable peptibody formulations |
| CN115636876A (zh) * | 2021-07-20 | 2023-01-24 | 重庆派金生物科技有限公司 | 胰高血糖素样肽-2突变体的定向化学偶联物及其应用 |
| CN117467025B (zh) * | 2023-12-28 | 2024-04-16 | 上海鼎新基因科技有限公司 | 一种抗vegf和补体双功能融合蛋白及其应用 |
| WO2025181330A1 (en) * | 2024-02-29 | 2025-09-04 | Vectivbio Ag | Dosage regimens for glucagon-like peptide 2 (glp-2) analogs |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1809318B1 (en) | 2004-11-01 | 2013-06-12 | NPS Pharmaceuticals, Inc. | Treatment of short bowel syndrome patients with colon-in-continuity |
| JP2009510999A (ja) | 2005-07-29 | 2009-03-19 | エーエムプロテイン コーポレイション | キメラ治療剤 |
| EA200801174A1 (ru) * | 2005-10-24 | 2009-02-27 | Сентокор, Инк. | Антитела-миметики glp-2, полипептиды, композиции, способы и применения |
| JP5290177B2 (ja) | 2006-08-31 | 2013-09-18 | セントカー・インコーポレーテツド | Ｇｌｐ−２ミメティボディ、ポリペプチド、組成物、方法および用途 |
| JP2008247789A (ja) | 2007-03-30 | 2008-10-16 | Kissei Pharmaceut Co Ltd | クローン病に伴う腸管狭窄の進展抑制用医薬組成物 |
| JP6206972B2 (ja) | 2011-09-12 | 2017-10-04 | アムニクス オペレーティング インコーポレイテッド | グルカゴン様ペプチド−２組成物およびその作製法および使用法 |
| UY34347A (es) * | 2011-09-26 | 2013-04-30 | Novartis Ag | Proteínas de función dual para tratar trastornos metabólicos |
| KR101895047B1 (ko) | 2011-12-30 | 2018-09-06 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체 |
| CN104540850B (zh) | 2012-05-03 | 2018-05-18 | 西兰制药公司 | 胰高血糖素样肽2(glp-2)类似物 |
| EP3082847A1 (en) * | 2013-12-20 | 2016-10-26 | Indiana University Research and Technology Corporation | Lipidated incretin receptor ligand human immunoglobulin fc-region fusion polypeptides |
| KR101825048B1 (ko) * | 2014-12-31 | 2018-02-05 | 주식회사 제넥신 | GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도 |
-
2018
- 2018-11-05 WO PCT/US2018/059175 patent/WO2019090209A1/en not_active Ceased
- 2018-11-05 CN CN201880071791.3A patent/CN111629745A/zh active Pending
- 2018-11-05 EP EP18872377.9A patent/EP3706774A4/en active Pending
- 2018-11-05 CA CA3079523A patent/CA3079523A1/en active Pending
- 2018-11-05 JP JP2020526107A patent/JP7296958B2/ja active Active
- 2018-11-05 AU AU2018360744A patent/AU2018360744A1/en not_active Abandoned
- 2018-11-05 US US16/761,606 patent/US11660328B2/en active Active
- 2018-11-05 KR KR1020207013387A patent/KR102825098B1/ko active Active
- 2018-11-05 BR BR112020008936-2A patent/BR112020008936A2/pt unknown
- 2018-11-05 IL IL274098A patent/IL274098B2/en unknown
- 2018-11-05 MX MX2020004620A patent/MX2020004620A/es unknown
- 2018-11-06 AR ARP180103232A patent/AR113835A1/es unknown
- 2018-11-06 TW TW107139266A patent/TWI911137B/zh active
-
2020
- 2020-05-04 ZA ZA2020/02080A patent/ZA202002080B/en unknown
-
2023
- 2023-06-13 JP JP2023096692A patent/JP7752152B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2020118172A (ru) | 2021-12-08 |
| JP7296958B2 (ja) | 2023-06-23 |
| JP7752152B2 (ja) | 2025-10-09 |
| AU2018360744A1 (en) | 2020-05-07 |
| CN111629745A (zh) | 2020-09-04 |
| MX2020004620A (es) | 2020-10-12 |
| IL274098A (en) | 2020-06-30 |
| IL274098B1 (en) | 2024-08-01 |
| EP3706774A4 (en) | 2021-09-08 |
| EP3706774A1 (en) | 2020-09-16 |
| BR112020008936A2 (pt) | 2020-10-20 |
| AR113835A1 (es) | 2020-06-17 |
| ZA202002080B (en) | 2025-11-26 |
| CA3079523A1 (en) | 2019-05-09 |
| US11660328B2 (en) | 2023-05-30 |
| JP2021502389A (ja) | 2021-01-28 |
| WO2019090209A1 (en) | 2019-05-09 |
| KR20200085763A (ko) | 2020-07-15 |
| TW201922279A (zh) | 2019-06-16 |
| JP2023107883A (ja) | 2023-08-03 |
| US20210169986A1 (en) | 2021-06-10 |
| KR102825098B1 (ko) | 2025-06-26 |
| TWI911137B (zh) | 2026-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274098B2 (en) | Glp-2 analogs and peptibodies for administration before during, or after surgery | |
| Grounds | Reasons for the degeneration of ageing skeletal muscle: a central role for IGF-1 signalling | |
| Wakabayashi et al. | Comprehensive approach to sarcopenia treatment | |
| Raffo et al. | A pulse rapamycin therapy for infantile spasms and associated cognitive decline | |
| JP2023107883A5 (https=) | ||
| JP2021502389A5 (https=) | ||
| Gligorov et al. | Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients | |
| RU2015101826A (ru) | Применение долгодействующих пептидов glp-1 | |
| JPWO2019107530A1 (ja) | 炎症性腸疾患の治療薬 | |
| FI3518932T3 (fi) | Eturauhassyövän hoito | |
| JP2019530648A5 (https=) | ||
| CA3218880A1 (en) | Methods and compositions for inducing brown adipogenesis | |
| US20240307404A1 (en) | Composition for Treatment of Muscular Disorders | |
| FI3352735T3 (fi) | Pitkitetysti vapauttavia olantsapiiniformulaatioita | |
| Lang et al. | Lithium neurotoxicity: the development of irreversible neurological impairment despite standard monitoring of serum lithium levels | |
| JP2022513351A5 (https=) | ||
| Tanaka et al. | The effectiveness of administering a minimal dose of octreotide long-term prior to surgery for insulinoma: report of a case | |
| US20260053769A1 (en) | Uses of selective androgen receptor modulator (sarm) compounds for quality weight loss | |
| US20250228804A1 (en) | Uses of selective androgen receptor modulator (sarm) compounds for quality weight loss | |
| US20260069564A1 (en) | Compositions comprising selective androgen receptor modulator compounds in combination with weight loss drugs and uses thereof for quality weight loss | |
| KR102914953B1 (ko) | 질레우톤(zileuton)을 유효성분으로 포함하는 피부 방사선 증후군 예방 또는 치료용 약학 조성물 | |
| Kim et al. | The timing of intra-coronary infusion of G-CSF mobilized peripheral blood stem cells influences cardiac function and in-stent restenosis in patients with myocardial infarction | |
| Tatiana et al. | McCune-Albright syndrome (MAS): clinical case | |
| Del Papa et al. | OP0143 Regional grafting of autologous adipose tissue is effective in inducing prompt healing of indolent digital ulcers in patients with systemic sclerosis: results of a monocentric randomised controlled study | |
| Bicknese et al. | GENDER DIFFERENCES AND OUTCOME TRENDS OVER TWO DECADES IN ACROMEGALY: A SINGLE CENTER STUDY IN 112 PATIENTS |